How do hormones and age affect Skene's gland size and function in people assigned female at birth?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Skene’s (paraurethral) glands are small, often “blueberry-sized” structures homologous to the male prostate and responsive to sex hormones; they secrete mucus-like fluid that can lubricate the urethra and may contribute to female ejaculation [1] [2]. Clinical and histologic reports link gland size, secretory activity and disease risk to age and hormonal milieu — for example, size and secretory proteins (like PSA) change with androgen exposure and most reported Skene’s gland cancers occur in older adults (median ages ~70–71 in series) — but systematic, population-level data on how hormones and ageing quantitatively alter gland volume or function are limited in current reporting [1] [3] [4] [5].
1. Anatomy and baseline function: the small gland with outsized debate
Skene’s glands sit on either side of the distal urethra in the vulvar vestibule, drain through tiny ducts, and produce a mucus-like secretion that moistens the urethra and may lubricate during sex; some researchers report proteins similar to male seminal proteins (PSA) in these secretions, which is why the glands are often called the “female prostate” [1] [2] [6]. Clinical summaries describe the glands as roughly the size of a small blueberry, but note substantial interindividual variation and tiny duct openings that make direct measurement difficult [1] [6].
2. Hormones: the biological link that researchers cite
Multiple sources state Skene’s glands are hormone-responsive: embryologically they share origins with the male prostate, they produce PSA, and authors assert estrogen and androgens influence gland histology and secretion — meaning sex hormones likely affect size, secretory activity, and sensitivity [2] [5] [1]. Case reports and reviews of malignancy suggest androgen-driven biology can appear in Skene’s gland tumors, and some tumours have been treated with androgen-deprivation–type strategies used in prostate cancer [4] [3]. Available sources do not provide large-scale, controlled studies documenting precisely how specific hormone levels (e.g., estradiol, testosterone) change normal gland size or baseline secretion rates across the life course [5].
3. Ageing: shrinkage, risk, and diagnostic patterns
Clinical case series and systematic reviews of malignant cases report that most documented Skene’s gland cancers present in older adults (median ages around 70–71 in identified series), implying malignant transformation is more often observed later in life; however cancers are extremely rare overall [4] [3] [7]. Animal studies and histologic reviews note age-related changes and hormone-regulated susceptibility to lesions in the homologous “female prostate” of animals, which researchers use as a model for human ageing effects [8]. Sources state that glandular histology can shift between glandular tissue and fibrous stroma with age and hormonal status, but they do not quantify normal age-related atrophy or enlargement in healthy people [5] [8].
4. Sexual function, ejaculation and anatomical variability
Some observational work links anatomic variability—number of visible duct openings or glandular plasticity—with reported ejaculatory phenomena: a study found women reporting fluid ejaculation had more external orifices on average than those who did not, suggesting anatomy and possibly gland size/activity correlate with functional outcomes [9]. But sources emphasize controversy: whether observed fluid derives from Skene’s glands, bladder, or combined sources remains debated [9] [2]. Available sources do not deliver definitive causal proof tying hormone levels or age to presence or absence of female ejaculation.
5. Clinical implications and uncertainty: infections, cysts, and very rare cancers
Clinically, Skene’s glands can become inflamed, obstructed (forming cysts), or—very rarely—malignant; case reports show some malignancies express PSA and respond to therapies analogous to prostate cancer care, reinforcing hormonal sensitivity in disease states [6] [10] [3]. But the literature is dominated by case reports and small series; there are no broad, prospective epidemiologic studies cited in the available sources establishing how menopause, hormonal contraception, HRT, or transgender hormonal treatments change gland volume or routine secretory function across populations [5] [1].
6. What we know, what we don’t, and advice for clinicians and patients
What we know: Skene’s glands are homologous to prostate tissue, produce PSA-like proteins, and show histologic/hormonal sensitivity with age-related disease patterns observed mostly in older adults [2] [4] [3]. What we don’t know from current reporting: precise, quantitative effects of specific hormone levels or typical ageing on normal gland volume and baseline secretion in representative populations; large-scale studies are absent [5]. Patients with local pain, swelling, unusual discharge, urinary symptoms, or periurethral masses should seek evaluation because cysts, infection, or rare malignancy are documented possibilities [6] [10].
Sources cited in this piece include clinical overviews, case series and histologic reviews that emphasize hormone links and age patterns but also reveal major gaps: the literature relies heavily on case reports, small cohorts, animal models and anatomical studies rather than large human longitudinal data [5] [1] [9] [4] [8] [3] [2].